Faruqi & Faruqi's Investigation into Capricor Therapeutics
Faruqi & Faruqi, LLP, a prominent law firm, is currently investigating potential claims on behalf of investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR). This investigation springs from concerns that the company may have misled investors regarding its lead drug candidate, deramiocel, for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
Importance of the Investigation
The legal representatives at Faruqi & Faruqi wish to reach out to investors who may have suffered losses exceeding $50,000 in Capricor. Investors during a specified timeframe who believe their financial interests have been negatively impacted are encouraged to engage in dialogue about their possible legal options. It’s essential to stay informed about rights and remedies available for those who have faced substantial losses.
Potential Violations and Their Consequences
Capricor has been alleged to have engaged in actions that violated federal securities laws by providing misleading information about its clinical trials and the viability of its products. Statements made by the company regarding the potential approval of deramiocel by the U.S. Food and Drug Administration (FDA) appear to have been overly optimistic, potentially masking significant deficiencies in their four-year safety and effectiveness data from earlier clinical studies.
Latest Developments on Capricor's Drug Candidate
On July 11, 2025, Capricor received a Complete Response Letter (CRL) from the FDA, which effectively rejected their application for the Biologics License Application (BLA). This communication from the FDA highlighted that the company did not satisfy the requirements for substantial evidence of effectiveness and indicated the need for further clinical data. Following the receipt of this letter, Capricor’s stock price saw a significant drop, prompting further scrutiny from investors and legal experts alike.
Investor Advocacy and Support
Faruqi & Faruqi encourages investors to share any information they have regarding Capricor’s conduct. The firm is particularly interested in insights from whistleblowers, former employees, shareholders, or anyone who might possess relevant details about the company's operations and communications. This collective information will play a crucial role in determining the next steps in the investigation.
The Role of the Lead Plaintiff
In class action lawsuits, a lead plaintiff is identified. This individual represents shareholders with similar grievances and directs the legal proceedings. Investors within the potential class can advocate for themselves by either electing to be a lead plaintiff or opting to remain anonymous, as the outcome of the case will still allow participation in any recovery.
How to Get Involved
Interested investors who have incurred significant losses in Capricor Therapeutics between defined periods should reach out to Faruqi & Faruqi partners for an evaluation of their case. Contact information is readily available, and the firm is prepared to assist with inquiries about legal rights concerning this unfolding matter.
Frequently Asked Questions
What triggered the investigation by Faruqi & Faruqi?
The investigation was initiated due to allegations that Capricor Therapeutics misrepresented information regarding its drug candidate, deramiocel, and its evaluation by the FDA.
Who can be considered a lead plaintiff in this case?
A lead plaintiff is typically an investor with significant losses who can adequately represent the interests of all affected shareholders in the litigation.
What actions should investors take if they have suffered losses?
Investors are encouraged to contact Faruqi & Faruqi to discuss their specific circumstances and potential legal options related to their investment losses.
What does it mean to opt-out of the class action?
Choosing to opt-out means you will not participate in any recovery and cannot influence the case as a lead plaintiff.
What information should investors provide to Faruqi & Faruqi?
Investors should provide details about their investments, timelines, and any communications they received from Capricor that could be pertinent to the investigation.
